Jeff Jones
Stock Analyst at Oppenheimer
(1.87)
# 3,256
Out of 5,042 analysts
94
Total ratings
28.24%
Success rate
-3.67%
Average return
Main Sectors:
Stocks Rated by Jeff Jones
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VTYX Ventyx Biosciences | Maintains: Outperform | $9 → $14 | $8.53 | +64.13% | 11 | Oct 27, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Outperform | $53 → $63 | $61.84 | +1.88% | 6 | Oct 1, 2025 | |
| PTHS Pelthos Therapeutics | Initiates: Outperform | $50 | $33.00 | +51.52% | 1 | Sep 2, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Outperform | $10 → $25 | $3.06 | +716.99% | 9 | Aug 27, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Outperform | $56 → $53 | $12.15 | +336.21% | 10 | Aug 6, 2025 | |
| AVBP ArriVent BioPharma | Maintains: Outperform | $39 → $44 | $18.73 | +134.92% | 3 | Jun 24, 2025 | |
| ALMS Alumis | Maintains: Outperform | $26 → $25 | $4.75 | +426.32% | 3 | May 15, 2025 | |
| ZURA Zura Bio | Maintains: Outperform | $19 → $17 | $3.84 | +342.71% | 4 | May 9, 2025 | |
| CRVS Corvus Pharmaceuticals | Reiterates: Outperform | $15 → $17 | $8.04 | +111.44% | 5 | May 9, 2025 | |
| IMCR Immunocore Holdings | Maintains: Outperform | $85 → $86 | $32.92 | +161.24% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $18 | $6.67 | +169.87% | 4 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.39 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $16 | $2.73 | +486.08% | 7 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $45 | $1.68 | +2,578.57% | 6 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $16.10 | - | 4 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.23 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $5.26 | - | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $1.41 | +963.83% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $75 | $0.47 | +16,015.17% | 2 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,600 → $1,100 | $5.75 | +19,030.43% | 2 | Nov 17, 2022 |
Ventyx Biosciences
Oct 27, 2025
Maintains: Outperform
Price Target: $9 → $14
Current: $8.53
Upside: +64.13%
Kymera Therapeutics
Oct 1, 2025
Maintains: Outperform
Price Target: $53 → $63
Current: $61.84
Upside: +1.88%
Pelthos Therapeutics
Sep 2, 2025
Initiates: Outperform
Price Target: $50
Current: $33.00
Upside: +51.52%
Chemomab Therapeutics
Aug 27, 2025
Maintains: Outperform
Price Target: $10 → $25
Current: $3.06
Upside: +716.99%
Corbus Pharmaceuticals Holdings
Aug 6, 2025
Maintains: Outperform
Price Target: $56 → $53
Current: $12.15
Upside: +336.21%
ArriVent BioPharma
Jun 24, 2025
Maintains: Outperform
Price Target: $39 → $44
Current: $18.73
Upside: +134.92%
Alumis
May 15, 2025
Maintains: Outperform
Price Target: $26 → $25
Current: $4.75
Upside: +426.32%
Zura Bio
May 9, 2025
Maintains: Outperform
Price Target: $19 → $17
Current: $3.84
Upside: +342.71%
Corvus Pharmaceuticals
May 9, 2025
Reiterates: Outperform
Price Target: $15 → $17
Current: $8.04
Upside: +111.44%
Immunocore Holdings
May 8, 2025
Maintains: Outperform
Price Target: $85 → $86
Current: $32.92
Upside: +161.24%
Jan 24, 2025
Maintains: Outperform
Price Target: $28 → $18
Current: $6.67
Upside: +169.87%
Dec 11, 2024
Downgrades: Perform
Price Target: n/a
Current: $3.39
Upside: -
Nov 22, 2024
Maintains: Outperform
Price Target: $22 → $16
Current: $2.73
Upside: +486.08%
Aug 8, 2024
Maintains: Outperform
Price Target: $48 → $45
Current: $1.68
Upside: +2,578.57%
Jun 7, 2024
Downgrades: Perform
Price Target: n/a
Current: $16.10
Upside: -
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.23
Upside: -
May 23, 2023
Downgrades: Perform
Price Target: n/a
Current: $5.26
Upside: -
May 11, 2023
Reiterates: Outperform
Price Target: $15
Current: $1.41
Upside: +963.83%
Mar 24, 2023
Reiterates: Outperform
Price Target: $75
Current: $0.47
Upside: +16,015.17%
Nov 17, 2022
Maintains: Outperform
Price Target: $1,600 → $1,100
Current: $5.75
Upside: +19,030.43%